Xtalks presents an exciting live webinar on Wednesday May 8, 2013 at 2:00pm EDT on the importance of Post-Marketing Observational Studies (PMOS). The event features Dr. John Samplis, Founder, CEO and Chief Scientific Officer of JSS Medical Research Inc.

The intrinsic differences between clinical trials and real-life drug treatment create safety gaps that can undermine the overall benefit for patients and value of marketed drugs

Toronto, Canada (PRWEB) April 23, 2013

The intrinsic differences between clinical trials and real-life drug treatment create safety gaps that can undermine the overall benefit for patients and value of marketed drugs.

Post-Approvals Clinical & Epidemiology Studies (PACES), including Post-Marketing Observational Studies (PMOS) and Phase IV studies, are the only sources of information that allows the assessment of real–life effectiveness and safety. These studies are ideal for generating data regarding patient adherence/compliance to treatment and its impact on effectiveness. Practice patterns and adherence to treatment guidelines by physicians can only be assessed with PACES.

In an exciting new webinar, Dr. John Samplis, Chief Scientific Officer at JSS Medical Research Inc., will cover:

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.